Author

Samantha M. Kiriluk

Observed name: Samantha Kiriluk

Institution: University of Washington

Observed institution: University of Washington

OpenAlex ID: A5024680009

ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.

2018 · Shailender Bhatia, Andrew Scott Brohl, et al. · Journal of Clinical Oncology · 12

ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.

2026 · Shailender Bhatia, Ted Gooley, et al. · Journal of Clinical Oncology · 5

TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma.

2024 · Natalie J. Miller, Grete Ambrazeviciute, et al. · Journal of Clinical Oncology · 3

Trick-MCC: Final results from the proof-of-concept investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma (NCT06056895).

2025 · Natalie J. Miller, Grete Ambrazeviciute, et al. · Journal of Clinical Oncology · 2

ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372

2022 · Wenwen Chen, Shailender Bhatia, et al. · Journal of Investigative Dermatology · 2

Works count: 5

Citation count: 24

H-index: 3

I10-index: 1